These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34813168)

  • 1. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
    El Hassab MA; Hemeda LR; Elsayed ZM; Al-Rashood ST; Abdel-Hamid Amin MK; Abdel-Aziz HA; Eldehna WM
    Chem Biodivers; 2022 Feb; 19(2):e202100719. PubMed ID: 34813168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
    Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
    Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
    White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
    Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
    Sachse M; Tenorio R; Fernández de Castro I; Muñoz-Basagoiti J; Perez-Zsolt D; Raïch-Regué D; Rodon J; Losada A; Avilés P; Cuevas C; Paredes R; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N; Risco C
    Antiviral Res; 2022 Apr; 200():105270. PubMed ID: 35231500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
    Martinez MA
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
    Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
    Guisado-Vasco P; Carralón-González MM; Aguareles-Gorines J; Martí-Ballesteros EM; Sánchez-Manzano MD; Carnevali-Ruiz D; García-Coca M; Barrena-Puertas R; de Viedma RG; Luque-Pinilla JM; Sotres-Fernandez G; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
    J Hematol Oncol; 2022 Jan; 15(1):4. PubMed ID: 35012608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
    Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
    Wakchaure PD; Ghosh S; Ganguly B
    J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.
    Asif M; Saleem M; Yaseen HS; Yehya AH; Saadullah M; Zubair HM; Oon CE; Khaniabadi PM; Khalid SH; Khan IU; Mahrukh
    Future Microbiol; 2021 Nov; 16(16):1289-1301. PubMed ID: 34689597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M
    Luo S; Huang K; Zhao X; Cong Y; Zhang JZH; Duan L
    Nanoscale; 2021 May; 13(17):8313-8332. PubMed ID: 33900318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
    Aguareles J; Villares Fernández P; Forné C; Martí-Ballesteros EM; Pradillo Fernández V; Sotres-Fernandez G; de la Fuente-Burguera A; Navarro-San Francisco C; Buzón-Martín LM; García-Delangue T; Aiello FT; Carnevali-Ruiz D; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; García-Casas A; Guisado-Vasco P
    Infect Dis (Lond); 2024 Jul; 56(7):575-580. PubMed ID: 38743059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
    Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; Fernandez de Orueta L; Torralba M; Fortun J; Vates R; Barberan J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijon P; Monereo A; Abad D; Zuñiga S; Sola I; Rodon J; Vergara-Alert J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Giron de Velasco P; Nieto A; Gomez J; Aviles P; Lubomirov R; Belgrano A; Sopesen B; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; McGovern BL; Rodriguez ML; Enjuanes L; Fernandez-Sousa JM; Krogan NJ; Jimeno JM; Garcia-Sastre A
    Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35012962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach.
    Singh R; Bhardwaj VK; Purohit R
    Comput Biol Med; 2021 Dec; 139():104965. PubMed ID: 34717229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.
    Tiwari V
    Int J Biol Macromol; 2021 Feb; 171():358-365. PubMed ID: 33421473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations.
    Arshia AH; Shadravan S; Solhjoo A; Sakhteman A; Sami A
    Comput Biol Med; 2021 Dec; 139():104967. PubMed ID: 34739968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.
    El Hassab MA; Ibrahim TM; Al-Rashood ST; Alharbi A; Eskandrani RO; Eldehna WM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):727-736. PubMed ID: 33685335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.